PR95340

Cambridge Nutranostics has developed a point-of-care prototype of OCCL test for testing blood plasma oxygen to monitor health in post stroke and TIA patients for dementia prevention

CAMBRIDGE, England, April 6, 2022 /PRNewswire=KYODO JBN/--

Cambridge Nutranostics Ltd, CNL, http://occltest.com has begun validation in

clinic of its first test prototype to assess and monitor plasma oxygen, the

part of the total blood O2, which can cross the capillary wall and deliver this

essential gas for tissue cell respiration.

Medical researchers from Cambridge University, Papworth Hospital and led by Dr

Ivan Petyaev, published their discovery that extracellular lipids,

lipoproteins, can be the main oxygen carrier in blood plasma

https://pubmed.ncbi.nlm.nih.gov/9505864/. It was found that a decline in OCCL,

a reduction of oxygen supply to tissues, might contribute to depression of

their functions and development of tissue hypoxia.

CNL has now successfully completed conversion of the established laboratory

format OCCL test to its express dry chemistry based point-of-care diagnostic,

the first affordable test of its kind able to be used not only by any health

care practitioner but also by an untrained person at home. This test would

require only one drop of capillary blood and provide results within minutes.

One of the company's first marketing targets are people at risk of developing

dementia, and in particularly those who have already experienced hypoxic or

ischemic clinical events such as a stroke or a transient ischemic attack, TIA.

Around 78 million people globally and 1 person out of 5 of 65 years or older in

Japan will have dementia in 2030.

Stroke or TIA as an acute oxygen deprivation shock to the brain makes it more

vulnerable and susceptible for future cerebral hypoxia accompanying development

of the dementia. https://pubmed.ncbi.nlm.nih.gov/35072712/ Approximately 30% of

stroke patients go on to develop cognitive dysfunction within 3 years.

The OCCL point-of-care test would allow a health care practitioner or the

person himself or herself, to assess the level of plasma oxygen and detect its

potential changes, which may not have any other clinical manifestations. Early

diagnosis of these changes may trigger additional medical examination and allow

measures to be taken to improve tissue oxygenation.

The company is expecting to launch this test in the first half of 2023. Alexey

Shulepov, the CEO of CNL, says "the company is proud to develop this test to

help to prevent development of dementia and reduce its impact on people's lives

in every country".

dm@occltest.com

SOURCE: Cambridge Nutranostics